Topical nicotinamide for seborrheic dermatitis: an open randomized study

References

• Elewski BE. Safe and effective treatment of seborrheic dermatitis. Cutis. 2009;83:333–338.
   PubMedGoogle Scholar
• Gupta AK, Bluhm R, Cooper EA, et al. Seborrheic dermatitis. Dermatol Clin. 2003;21:401–412.
   Google Scholar
• Bukvić Mokos Z, Kralj M, Basta-Juzbašić A, Lakoš Jukić I. Seborrheic dermatitis: an update. Acta Dermatovenerol Croat. 2012;20:98–104.
   PubMed Web of Science ®Google Scholar
• Reichrath J. Antimycotics: why are they effective in the treatment of seborrheic dermatitis? Dermatology. 2004;208:174–175.
   Google Scholar
• Dobrev H, Zissova L. Effect of ketoconazole 2% shampoo on scalp sebum level in patients with seborrhoeic dermatitis. Acta Derm Venereol. 1997;77:132–134.
   Google Scholar
• Piérard GE, Piérard-Franchimont C, Van Cutsem J, Rurangirwa A, Hoppenbrouwers ML, Schrooten P. Ketoconazole 2% emulsion in the treatment of seborrheic dermatitis. J Dermatol. 1991;30:806–809.
   Google Scholar
• Seckin D, Gurbuz O, Akin O. Metronidazole 0.75% gel vs. ketoconazole 2% cream in the treatment of facial seborrheic dermatitis: a randomized, double-blind study. J Eur Acad Dermatol Venereol. 2007;21:345–350.
   PubMed Web of Science ®Google Scholar
• Chosidow O, Maurette C, Dupuy P. Randomized, open-labeled, non-inferiority study between ciclopiroxolamine 1% cream and ketoconazole 2% foaming gel in mild to moderate facial seborrheic dermatitis. Dermatology. 2003;206:233–240.
   PubMed Web of Science ®Google Scholar
• Piérard-Franchimont C, Piérard GE. A double-blind placebo-controlled study of ketoconazole + desonide gel combination in the treatment of facial seborrheic dermatitis. Dermatology. 2002;204:344–347.
   PubMed Web of Science ®Google Scholar
• Dreno B, Chosidow O, Revuz J, Moyse D; Study Investigator Group. Lithium gluconate 8% vs ketoconazole 2% in the treatment of seborrhoeic dermatitis: a multicentre, randomized study. Br J Dermatol. 2003;148:1230–1236.
   PubMed Web of Science ®Google Scholar
• Shalita AR, Smith JG, Parish LC, Sofman MS, Chalker DK. Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. Int J Dermatol. 1995;34:434–437.
   PubMed Web of Science ®Google Scholar
• Fivenson DP, Breneman DL, Rosen GB, Hersh CS, Cardone S, Mutasim D. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol. 1994;130:753–758.
   PubMedGoogle Scholar
• Koc E, Arca E, Kose O, Akar A. An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis. J Dermatolog Treat. 2009;20:4–9.
   PubMed Web of Science ®Google Scholar
• Maiese K, Chong ZZ, Hou J, Shang YC. The vitamin nicotinamide: translating nutrition into clinical care. Molecules. 2009;14:3446–3485.
   PubMed Web of Science ®Google Scholar
• Reddy S, Young M, Ginn S. Immunoexpression of interleukin-1beta in pancreatic islets of NOD mice during cyclophosphamide-accelerated diabetes: co-localization in macrophages and endocrine cells and its attenuation with oral nicotinamide. Histochem J. 2001;33:317–327.
   Google Scholar
• Chen CF, Wang D, Hwang CP, Liu HW, Wei J, Lee RP, et al. The protective effect of niacinamide on ischemia-reperfusion-induced liver injury. J Biomed Sci. 2001;8:446–452.
   Google Scholar
• Moberg L, Olsson A, Berne C, Felldin M, Foss A, Källen R, et al. Nicotinamide inhibits tissue factor expression in isolated human pancreatic islets: implications for clinical islet transplantation. Transplantation. 2003;76:1285–1288.
   PubMedGoogle Scholar
• Ungerstedt JS, Blömback M, Söderström T. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin Exp Immunol. 2003;131:48–52.
   PubMed Web of Science ®Google Scholar
• Traister A, Breitman I, Bar-Lev E, Zvibel I, Harel A, Halpern Z, et al. Nicotinamide induces apoptosis and reduces collagen I and pro-inflammatory cytokines expression in rat hepatic stellate cells. Scand J Gastroenterol. 2005;40:1226–1234.
   Google Scholar
• Pero RW, Axelsson B, Siemann D, Chaplin D, Dougherty G. Newly discovered anti-inflammatory properties of the benzamides and nicotinamides. Mol Cell Biochem. 1999;193:119–125.
   Google Scholar
• Hassa PO, Hottiger MO. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. Front Biosci. 2008;13:3046–3082.
   PubMed Web of Science ®Google Scholar
• Yélamos J, Schreiber V, Dantzer F. Toward specific functions of poly(ADP-ribose) polymerase-2. Trends Mol Med. 2008;14:169–178.
   PubMed Web of Science ®Google Scholar
• Fabbrocini G, Annunziata MC, D'Arco V, De Vita V, Lodi G, Mauriello MC, et al. Acne scars: pathogenesis, classification and treatment. Dermatol Res Pract. 2010;2010:893080.
   PubMedGoogle Scholar
• Virág L, Szabó C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev. 2002;54:375–429.
   PubMed Web of Science ®Google Scholar
• Szabó E, Virág L, Bakondi E, Gyüre L, Haskó G, Bai P, et al. Peroxynitrite production, DNA breakage, and poly(ADP-ribose) polymerase activation in a mouse model of oxazolone-induced contact hypersensitivity. J Invest Dermatol. 2001;117:74–80.
   PubMed Web of Science ®Google Scholar
• Tanno O, Ota Y, Kitamura N, Katsube T, Inoue S. Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrier. Br J Dermatol. 2000;143:524–531.
   PubMed Web of Science ®Google Scholar